



**KEMENTERIAN KESIHATAN MALAYSIA**  
(Ministry of Health Malaysia)  
**Bahagian Regulatori Farmasi Negara (NPRA)**  
Lot 36, Jalan Prof. Diraja Ungku Aziz,  
46200 Petaling Jaya  
Selangor  
MALAYSIA

No. Telefon : 03 - 7883 5400  
Portal Rasmi : www.npra.gov.my

Ruj. Kami : NPRA.600-1/9/13 (39) Jld.1  
Tarikh : 15 April 2024

**SEMUA PEMEGANG PENDAFTARAN PRODUK**

**SEMUA PERSATUAN BERKENAAN  
(SEPERTI DI SENARAI EDARAN)**

Tuan / Puan,

**PERATURAN-PERATURAN KAWALAN DADAH DAN KOSMETIK 1984  
ARAHAN PENGARAH PERKHIDMATAN FARMASI BILANGAN 8 TAHUN 2024  
DIREKTIF UNTUK SEMUA PRODUK YANG MENGANDUNGI CIPROFLOXACIN,  
MOXIFLOXACIN, LEVOFLOXACIN DAN OFLOXACIN UNTUK KEGUNAAN SISTEMIK  
(SEDIAAN ORAL DAN INJEKSI) : PENGEMASKINIAN SISIP BUNGKUSAN DAN  
RISALAH MAKLUMAT UBAT UNTUK PENGGUNA (RiMUP) DENGAN MAKLUMAT  
KESELAMATAN BERKAITAN RISIKO *SUICIDAL BEHAVIOUR***

Dengan hormatnya saya merujuk kepada perkara di atas.

2. Dikemukakan Arahan Pengarah Perkhidmatan Farmasi Bilangan 8 Tahun 2024, Direktif untuk semua produk yang mengandungi ciprofloxacin, moxifloxacin, levofloxacin dan ofloxacin untuk kegunaan sistemik (sediaan oral dan injeksi) : Pengemaskinian sisip bungkusan dan Risalah Maklumat Ubat Untuk Pengguna (RiMUP) dengan maklumat keselamatan berkaitan risiko *suicidal behaviour* untuk makluman dan perhatian tuan/puan.

3. Tuan / Puan adalah diarahkan untuk mematuhi keperluan tersebut.

Sekian, terima kasih.

**"MALAYSIA MADANI"**

**"BERKHIDMAT UNTUK NEGARA"**

Saya yang menjalankan amanah,

**(ROSILAWATI BINTI AHMAD) RPh.1413**

Pengarah  
Bahagian Regulatori Farmasi Negara  
Kementerian Kesihatan Malaysia

sak/sab/hlaj/pkpsr/npra

✉ suhailah@npra.gov.my / lisaassakina@npra.gov.my  
☎ +603 - 7883 5463 / 5467



**ARAHAN DI BAWAH PERATURAN 29 PERATURAN – PERATURAN  
KAWALAN DADAH DAN KOSMETIK 1984**

---

**BILANGAN 8 TAHUN 2024**

---

**DIREKTIF UNTUK SEMUA PRODUK YANG MENGANDUNGI CIPROFLOXACIN,  
MOXIFLOXACIN, LEVOFLOXACIN DAN OFLOXACIN UNTUK KEGUNAAN  
SISTEMIK (SEDIAAN ORAL DAN INJEKSI) : PENGEMASKINIAN SISIP  
BUNGKUSAN DAN RISALAH MAKLUMAT UBAT UNTUK PENGGUNA (RiMUP)  
DENGAN MAKLUMAT KESELAMATAN BERKAITAN RISIKO *SUICIDAL  
BEHAVIOUR***

**1. TUJUAN**

- 1.1 Jawatankuasa Penasihat Kesan Advers Ubat Kebangsaan (MADRAC) dalam mesyuarat kali ke-189 pada 14 Mac 2024 telah mencadangkan pengemaskinian sisip bungkusan dan Risalah Maklumat Ubat Untuk Pengguna (RiMUP) bagi semua produk yang mengandungi ciprofloxacin, moxifloxacin, levofloxacin dan ofloxacin untuk kegunaan sistemik (sediaan oral dan injeksi) dengan maklumat keselamatan berkaitan risiko *suicidal behaviour*.
- 1.2 Di bawah peruntukan Peraturan 8, Peraturan-Peraturan Kawalan Dadah dan Kosmetik 1984 (PKDK 1984), Pihak Berkuasa Kawalan Dadah (PBKD) dalam mesyuarat kali ke-395 pada 4 April 2024 telah membuat keputusan berkenaan perkara tersebut di atas.
- 1.3 Sehubungan dengan itu, arahan ini dikeluarkan oleh Pengarah Perkhidmatan Farmasi di bawah peruntukan Peraturan 29, PKDK 1984 untuk memaklumkan Pemegang Pendaftaran Produk (PRH) berhubung perkara ini.


## 2. PELAKSANAAN


- 2.1 Oleh itu, arahan-arahan seperti di **Lampiran A** perlu dipatuhi untuk semua produk yang mengandungi ciprofloxacin, moxifloxacin, levofloxacin dan ofloxacin untuk kegunaan sistemik (sediaan oral dan injeksi).
- 2.2 Tarikh pelaksanaan keperluan mengemas kini maklumat berkenaan pada semua produk tersebut di atas adalah seperti berikut :
- (a) Permohonan baharu dan produk yang sedang dalam proses penilaian : **1 Mei 2024**
  - (b) Produk berdaftar : **1 November 2024**
- 2.3 Permohonan pindaan pada sisip bungkus dan RiMUP bagi produk berdaftar perlu dikemukakan sebagai permohonan variasi *MiV PA2 - Change of product labeling (in accordance to country specific labeling requirement)*.

## 3. TARIKH KUAT KUASA

- 3.1 Tarikh kuat kuasa arahan ini ialah mulai **1 Mei 2024**.

“BERKHIDMAT UNTUK NEGARA”

  
 (NORHALIZA BINTI A HALIM) RPh. 1750  
 Pengarah Perkhidmatan Farmasi  
 Kementerian Kesihatan Malaysia

 sak/sab/nia/pkpsr/npra

- s.k.
1. Timbalan Ketua Pengarah Kesihatan (Kesihatan Awam), Kementerian Kesihatan Malaysia (KKM)
  2. Timbalan Ketua Pengarah Kesihatan (Perubatan), KKM
  3. Pengarah Bahagian Regulatori Farmasi Negara, KKM
  4. Pengarah Bahagian Amalan dan Perkembangan Farmasi, KKM
  5. Pengarah Bahagian Penguatkuasaan Farmasi, KKM
  6. Pengarah Bahagian Dasar dan Perancangan Strategik Farmasi, KKM

**LAMPIRAN A**

DIREKTIF UNTUK SEMUA PRODUK YANG MENGANDUNGI CIPROFLOXACIN, MOXIFLOXACIN, LEVOFLOXACIN DAN OFLOXACIN UNTUK KEGUNAAN SISTEMIK (SEDIAN ORAL DAN INJEKSI) : PENGEMASKINIAN SISIP BUNGGUSAN DAN RISALAH MAKLUMAT UBAT UNTUK PENGGUNA (RiMUP) DENGAN MAKLUMAT KESELAMATAN BERKAITAN RISIKO *SUICIDAL BEHAVIOUR*

**(1) SPECIFIC LABELLING REQUIREMENTS (SUBSTANCE SPECIFIC) FOR  
CIPROFLOXACIN**

The following statements shall be included in the package insert and Consumer Medication Information Leaflet (RiMUP) for products containing ciprofloxacin for systemic use (oral and injection dosage forms):

**Package Insert****a) Warnings & Precautions:****Psychiatric reactions**

Psychiatric reactions may occur even after the first administration of fluoroquinolones, including [Product name]. In rare cases, depression or psychotic reactions can progress to suicidal ideations/thoughts and self-injurious behaviour, such as attempted or completed suicide (see section 'Undesirable effects'). In the event that the patient develops these reactions, [Product name] should be discontinued and appropriate measures instituted. Caution is recommended if [Product name] is to be used in psychotic patients or in patients with a history of psychiatric disease

**b) Adverse Effects/ Undesirable Effects:****Psychiatric disorders**

Rare: Depression (potentially culminating in suicidal ideations/ thoughts or suicide attempts and completed suicide)

Very Rare: Psychotic reactions (potentially culminating in suicidal ideations/ thoughts or suicide attempts and completed suicide)

**LAMPIRAN A**

DIREKTIF UNTUK SEMUA PRODUK YANG MENGANDUNGI CIPROFLOXACIN, MOXIFLOXACIN, LEVOFLOXACIN DAN OFLOXACIN UNTUK KEGUNAAN SISTEMIK (SEDIAAN ORAL DAN INJEKSI) : PENGEMASKINIAN SISIP BUNGGUSAN DAN RISALAH MAKLUMAT UBAT UNTUK PENGGUNA (RiMUP) DENGAN MAKLUMAT KESELAMATAN BERKAITAN RISIKO *SUICIDAL BEHAVIOUR*

**(1) SPECIFIC LABELLING REQUIREMENTS (SUBSTANCE SPECIFIC) FOR  
CIPROFLOXACIN****Consumer Medication Information Leaflet (RiMUP)****a) While you are using it:**

You may experience mental health problems even when taking/ using fluoroquinolone antibiotics, including [Product name] for the first time. In very rare cases depression or mental health problems have led to suicidal thoughts and self-injurious behaviour such as suicide attempts. If you develop such reactions, stop taking/ using [Product name] and inform your doctor immediately.

**b) Side effects:**

Rare: Depression (potentially leading to thoughts of suicide, suicide attempts, or completed suicide), or hallucinations

Very rare: Psychotic reactions potentially leading to thoughts of suicide, suicide attempts, or completed suicide

**LAMPIRAN A**

DIREKTIF UNTUK SEMUA PRODUK YANG MENGANDUNGI CIPROFLOXACIN, MOXIFLOXACIN, LEVOFLOXACIN DAN OFLOXACIN UNTUK KEGUNAAN SISTEMIK (SEDIAN ORAL DAN INJEKSI) : PENGEMASKINIAN SISIP BUNGGUSAN DAN RISALAH MAKLUMAT UBAT UNTUK PENGGUNA (RiMUP) DENGAN MAKLUMAT KESELAMATAN BERKAITAN RISIKO SUICIDAL BEHAVIOUR

**(2) SPECIFIC LABELLING REQUIREMENTS (SUBSTANCE SPECIFIC) FOR  
MOXIFLOXACIN**

The following statements shall be included in the package insert and Consumer Medication Information Leaflet (RiMUP) for products containing moxifloxacin for systemic use (oral and injection dosage forms):

**Package Insert**

**a) Warnings & Precautions:**

Psychiatric reactions

Psychiatric reactions may occur even after the first administration of fluoroquinolones, including [Product name]. In rare cases, depression or psychotic reactions can progress to suicidal ideations/thoughts and self-injurious behaviour, such as attempted or completed suicide (see section 'Undesirable effects'). In the event that the patient develops these reactions, [Product name] should be discontinued and appropriate measures instituted. Caution is recommended if [Product name] is to be used in psychotic patients or in patients with a history of psychiatric disease

**b) Adverse Effects/ Undesirable Effects:**

Psychiatric disorders

Rare: Depression (in very rare cases potentially culminating in self- injurious behaviour, such as suicidal ideation/ thoughts or suicide attempts), Hallucination

Very Rare: Psychotic reactions (potentially culminating in self-injurious behaviour, such as suicidal ideation/ thoughts or suicide attempts)

**LAMPIRAN A**

DIREKTIF UNTUK SEMUA PRODUK YANG MENGANDUNGI CIPROFLOXACIN, MOXIFLOXACIN, LEVOFLOXACIN DAN OFLOXACIN UNTUK KEGUNAAN SISTEMIK (SEDIAN ORAL DAN INJEKSI) : PENGEMASKINIAN SISIP BUNGGUSAN DAN RISALAH MAKLUMAT UBAT UNTUK PENGGUNA (RiMUP) DENGAN MAKLUMAT KESELAMATAN BERKAITAN RISIKO *SUICIDAL BEHAVIOUR*

**(2) SPECIFIC LABELLING REQUIREMENTS (SUBSTANCE SPECIFIC) FOR  
MOXIFLOXACIN****Consumer Medication Information Leaflet (RiMUP)****a) While you are using it:**

You may experience mental health problems even when taking/ using fluoroquinolone antibiotics, including [Product name] for the first time. In very rare cases depression or mental health problems have led to suicidal thoughts and self-injurious behaviour such as suicide attempts. If you develop such reactions, stop taking/ using [Product name] and inform your doctor immediately.

**b) Side effects:**

Rare: Depression (in very rare cases leading to self-harm, such as suicidal ideations/ thoughts (desire to kill oneself), or suicide attempts), hallucinations

Very rare: Psychotic reactions (potentially leading to self-harm, such as suicidal ideations/ thoughts (desire to kill oneself), or suicide attempts)

**LAMPIRAN A**

DIREKTIF UNTUK SEMUA PRODUK YANG MENGANDUNGI CIPROFLOXACIN, MOXIFLOXACIN, LEVOFLOXACIN DAN OFLOXACIN UNTUK KEGUNAAN SISTEMIK (SEDIAAN ORAL DAN INJEKSI) : PENGEMASKINIAN SISIP BUNGGUSAN DAN RISALAH MAKLUMAT UBAT UNTUK PENGGUNA (RiMUP) DENGAN MAKLUMAT KESELAMATAN BERKAITAN RISIKO SUICIDAL BEHAVIOUR

### (3) SPECIFIC LABELLING REQUIREMENTS (SUBSTANCE SPECIFIC) FOR LEVOFLOXACIN

The following statements shall be included in the package insert and Consumer Medication Information Leaflet (RiMUP) for products containing levofloxacin for systemic use (oral and injection dosage forms):

#### **Package Insert**

#### **a) Warnings & Precautions:**

##### Psychiatric reactions

Psychiatric reactions may occur even after the first administration of fluoroquinolones, including [Product name]. In rare cases, depression or psychotic reactions can progress to suicidal ideations/thoughts and self-injurious behaviour, such as attempted or completed suicide (see section 'Undesirable effects'). In the event that the patient develops these reactions, [Product name] should be discontinued and appropriate measures instituted. Caution is recommended if [Product name] is to be used in psychotic patients or in patients with a history of psychiatric disease

#### **b) Adverse Effects/ Undesirable Effects:**

##### Psychiatric disorders

Rare: Psychotic reactions (with e.g. hallucination, paranoia), Depression

Very Rare: Psychotic reactions (potentially culminating in suicidal ideations/ thoughts or suicide attempts and completed suicide)

Not known (cannot be estimated from available data): Psychotic disorders with self-endangering behavior including suicidal ideation or suicide attempt



**LAMPIRAN A**

DIREKTIF UNTUK SEMUA PRODUK YANG MENGANDUNGI CIPROFLOXACIN, MOXIFLOXACIN, LEVOFLOXACIN DAN OFLOXACIN UNTUK KEGUNAAN SISTEMIK (SEDIAAN ORAL DAN INJEKSI) : PENGEMASKINIAN SISIP BUNGGUSAN DAN RISALAH MAKLUMAT UBAT UNTUK PENGGUNA (RiMUP) DENGAN MAKLUMAT KESELAMATAN BERKAITAN RISIKO *SUICIDAL BEHAVIOUR*

**(3) SPECIFIC LABELLING REQUIREMENTS (SUBSTANCE SPECIFIC) FOR  
LEVOFLOXACIN****Consumer Medication Information Leaflet (RiMUP)****a) While you are using it:**

You may experience mental health problems even when taking/ using fluoroquinolone antibiotics, including [Product name] for the first time. In very rare cases depression or mental health problems have led to suicidal thoughts and self-injurious behaviour such as suicide attempts. If you develop such reactions, stop taking/ using [Product name] and inform your doctor immediately.

**b) Side effects:**

Rare: Change in your opinion and thoughts (psychotic reactions) with a risk of having suicidal thoughts or actions, hallucination, depression

Very rare: Psychotic behaviour

Not known (frequency cannot be estimated from the available data): Psychotic reactions with a risk of having suicidal thoughts or actions

**LAMPIRAN A**

DIREKTIF UNTUK SEMUA PRODUK YANG MENGANDUNGI CIPROFLOXACIN, MOXIFLOXACIN, LEVOFLOXACIN DAN OFLOXACIN UNTUK KEGUNAAN SISTEMIK (SEDIAN ORAL DAN INJEKSI) : PENGEMASKINIAN SISIP BUNGKUSAN DAN RISALAH MAKLUMAT UBAT UNTUK PENGGUNA (RiMUP) DENGAN MAKLUMAT KESELAMATAN BERKAITAN RISIKO SUICIDAL BEHAVIOUR

**(4) SPECIFIC LABELLING REQUIREMENTS (SUBSTANCE SPECIFIC) FOR OFLOXACIN**

The following statements shall be included in the package insert and Consumer Medication Information Leaflet (RiMUP) for products containing ofloxacin for systemic use (oral and injection dosage forms):

**Package Insert****a) Warnings & Precautions:****Psychiatric reactions**

Psychiatric reactions may occur even after the first administration of fluoroquinolones, including [Product name]. In rare cases, depression or psychotic reactions can progress to suicidal ideations/thoughts and self-injurious behaviour, such as attempted or completed suicide (see section 'Undesirable effects'). In the event that the patient develops these reactions, [Product name] should be discontinued and appropriate measures instituted. Caution is recommended if [Product name] is to be used in psychotic patients or in patients with a history of psychiatric disease

**b) Adverse Effects/ Undesirable Effects:****Psychiatric disorders**

Rare: Psychotic disorder (for e.g.hallucination)

Very Rare: Psychotic behaviour

Frequency not known (cannot be estimated from the available data): Psychotic disorders and depression with self-endangering behavior including suicidal ideation or suicide attempt

**LAMPIRAN A**

DIREKTIF UNTUK SEMUA PRODUK YANG MENGANDUNGI CIPROFLOXACIN, MOXIFLOXACIN, LEVOFLOXACIN DAN OFLOXACIN UNTUK KEGUNAAN SISTEMIK (SEDIAAN ORAL DAN INJEKSI) : PENGEMASKINIAN SISIP BUNGGUSAN DAN RISALAH MAKLUMAT UBAT UNTUK PENGGUNA (RiMUP) DENGAN MAKLUMAT KESELAMATAN BERKAITAN RISIKO *SUICIDAL BEHAVIOUR*

**(4) SPECIFIC LABELLING REQUIREMENTS (SUBSTANCE SPECIFIC) FOR  
OFLOXACIN****Consumer Medication Information Leaflet (RiMUP)****a) While you are using it:**

You may experience mental health problems even when taking/ using fluoroquinolone antibiotics, including [Product name] for the first time. In very rare cases depression or mental health problems have led to suicidal thoughts and self-injurious behaviour such as suicide attempts. If you develop such reactions, stop taking/ using [Product name] and inform your doctor immediately.

**b) Side effects:**

Rare: Psychotic reactions with a risk of having suicidal thoughts or actions, hallucination, depression

Very rare: Psychotic behaviour

Not known (frequency cannot be estimated from the available data): Psychotic reactions with a risk of having suicidal thoughts or actions